• 1
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer Statistics, 2003. Cancer J Clin. 2003; 53: 526.
  • 2
    Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986; 46: 25782581.
  • 3
    Machiavelli MR, Romero AO, Perez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am. 1998; 4: 125131.
  • 4
    McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989; 124: 2125.
  • 5
    Maini CL, Tofani A, Sciuto R, et al. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med. 1997; 38: 15461550.
  • 6
    Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [Technetium-99m]-sestamibi scintimammography. Cancer. 1999; 85: 24102423.
  • 7
    Tiling R, Kessler M, Untch M, et al. Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography. Onkologie. 2003; 26: 2731.
  • 8
    Mankoff DA, Dunnwald LK, Gralow JR, et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol. 2002; 29: 719727.
  • 9
    Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002; 43: 500509.
  • 10
    Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003; 44: 18061814.
  • 11
    Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997; 80: 18031804.
  • 12
    Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Reubens RD. Assessment of response to therapy in advanced breast cancer. Cancer. 1977; 39: 12891294.
  • 13
    Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001: 9610214.
  • 14
    Diggles L, Mena I, Khalkhali I. Technical aspects of prone dependent-breast scintimammography. J Nucl Med Technol. 1994; 22: 165170.
  • 15
    Dunnwald LK, Hartnett SD, Mankoff DA. Utility and reproducibility of semiquantitative analysis of sestamibi breast images. J Nucl Med Technol. 1997; 25: 106109.
  • 16
    Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995; 71: 146149.
  • 17
    Pertschuk LP, Feldman JG, Kim YD, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996; 77: 25142519.
  • 18
    Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992; 84: 845855.
  • 19
    Kalbfleisch JD, Prentice RL. The statistical analysis of failure time Data. 2nd edition. New York: John Wiley & Sons, 2002.
  • 20
    Kao C, ChangLai S, Chieng P, Yen T. Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma: relation to patient prognosis and chemotherapy response—a preliminary report. Cancer. 1998; 83: 6468.
  • 21
    Komori T, Narabayashi I, Matsui R, Sueyoshi K, Aratani T, Utsunomiya K. Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer-preliminary report. Ann Nucl Med. 2000; 14: 415420.
  • 22
    Yuksel M, Cermik F, Doganay L, et al. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis. Eur J Nucl Med Mol Imaging. 2002; 29: 876881.
  • 23
    Kao C, Wang S, Yeh S. Tc-99m MIBI uptake in breast carcinoma and axillary lymph node metastases. Clin Nucl Med. 1994; 19: 898900.
  • 24
    Khalkahli I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg. 1994; 178: 491497.
  • 25
    Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med. 1995; 36: 17581765.
  • 26
    Palmedo H, Schomburg A, Grunwald F, Mallmann P, Krebs D, Biersack H-J. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med. 1996; 37: 626630.
  • 27
    Del Vecchio S, Ciarmello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med. 1997; 24: 150159.
  • 28
    Ciarmiello A, Vecchio SD, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998; 16: 16771683.
  • 29
    Kostakoglu L, Ruacan S, Ergun E, Sayek I, Elahi N, Bekdik C. Influence of heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. J Nucl Med. 1998; 39: 10211026.
  • 30
    Del Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of p-glycoprotein expression in untreated breast cancer patients. J Nucl Med. 1997; 38: 13481351.
  • 31
    Okada RD, Glover D, Gaffney T, Willimas S. Myocardial kinetics of technetium-99m hexakis 2-methoxy-2methylpropyl-isonitrile. Circulation. 1988; 77: 491498.
  • 32
    Wackers FJT, Berman DS, Maddahi J. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med. 1989; 30: 301311.
  • 33
    Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001; 8: 549559.
  • 34
    Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC. Breast carcinoma: measurement of tumor response to primary medical therapy with color flow Doppler imaging. Radiology. 1994; 190: 825830.
  • 35
    Peters-Engl C, Frank W, Leodolter S, Medl M. Tumor flow in malignant breast tumors measured by Doppler ultrasound: an independent predictor of survival. Breast Cancer Res Treat. 1999; 54: 6571.
  • 36
    Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996; 78: 91100.
  • 37
    Gilles R, Guinebretiere JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology. 1994; 191: 633638.